I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
September 29, 2016
… Is a zero sum game …
The game is often used as a choosing method in a way similar to, share dipping, short tipping and buying based on throwing dice
I answer one question; in which company should investors put, keep and commit their money!
Where is “our” universe going today? Astute investors subscribe, you should too!
I say what others won't, so you can do what others can't!
Read me or discount me, I make investors’ money!
WHO AM I?...Advancing warnings of danger or safety
Content and context’ sensitivity to markets make them an indicator of share pricing deterioration or appreciation
...Why do investors need me?
Interpretation and translation of material events reset the conversation, perception, and sentiment, volume and audience!
July 4, 2016
What difference does a $2.19 subscription a day make for 73 issues a month, 876 posts a year and the lack of a portfolio ... enema!
Subscribe: http://www.regmedinvestors.com/create-account
September 28, 2016
The market jumps, “our universe dumps as the iShares Nasdaq Biotechnology ETF (IBB) slipped -0.81% and expectation leaves us twiddling our thumbs
Pre-open indication’s tally: 5 hits <ATHX, BLUE, CLLS, KITE and STML> and 0 miss <>
I answer one question; in which company should investors put, keep and commit their money!
Do you care what happened today, you should because it has implications to Thursday's sector activity?
Subscribe or lose!
I say what others won't, so you can do what others can't!
September 27, 2016
For LentiGlobin drug product in the treatment of patients with transfusion-dependent beta-thalassemia (TDT).
September 16, 2016
Data shows it might be possible to achieve the same degree of CNV inhibition using an intra-vitreally delivered novel vector with an optimized AAV capsid, expression cassette, and anti-VEGF cDNA as the standard-of-care
September 16, 2016
HSGX will sell 2,653,553 shares at a price of $2.25 per share and 24,158.8688 shares of newly created Series A Convertible Preferred Stock, which shares of preferred stock are convertible into approximately 10,679,781 shares of common stock. Purchasers will receive warrants to purchase up to approximately 13,333,334 shares of common stock at an exercise price of $2.25 per share.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
7 hours 30 min ago
Flat open expected; RegMed Investors’ pre-open, rock, paper scissors …
© 2016 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
